FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2079138963> ?p ?o ?g. }

• W2079138963 endingPage "2588" @default.
• W2079138963 startingPage "2581" @default.
• W2079138963 abstract "Abstract Maintenance therapy has become a hot field in myeloma, and it may be particularly relevant in elderly patients because the major benefit results from the initial therapy. We report the results of a randomized comparison of maintenance with bortezomib plus thalidomide (VT) or prednisone (VP) in 178 elderly untreated myeloma patients who had received 6 induction cycles with bortezomib plus either melphalan and prednisone or thalidomide and prednisone. The complete response (CR) rate increased from 24% after induction up to 42%, higher for VT versus VP (46% vs 39%). Median progression-free survival (PFS) was superior for VT (39 months) compared with VP (32 months) and overall survival (OS) was also longer in VT patients compared with VP (5-year OS of 69% and 50%, respectively) but the differences did not reach statistical significance. CR achievement was associated with a significantly longer PFS (P < .001) and 5-year OS (P < .001). The incidence of G3-4 peripheral neuropathy was 9% for VT and 3% for VP. Unfortunately, this approach was not able to overcome the adverse prognosis of cytogenetic abnormalities. In summary, these maintenance regimens result in a significant increase in CR rate, remarkably long PFS, and acceptable toxicity profile. The trial is registered at www.clinicaltrials.gov as NCT00443235." @default.
• W2079138963 created "2016-06-24" @default.
• W2079138963 creator A5003094323 @default.
• W2079138963 creator A5004897410 @default.
• W2079138963 creator A5006676110 @default.
• W2079138963 creator A5013472737 @default.
• W2079138963 creator A5016479494 @default.
• W2079138963 creator A5020989412 @default.
• W2079138963 creator A5029159537 @default.
• W2079138963 creator A5031837957 @default.
• W2079138963 creator A5034182883 @default.
• W2079138963 creator A5035866456 @default.
• W2079138963 creator A5040325515 @default.
• W2079138963 creator A5047866471 @default.
• W2079138963 creator A5054952877 @default.
• W2079138963 creator A5059482051 @default.
• W2079138963 creator A5073739479 @default.
• W2079138963 creator A5075422618 @default.
• W2079138963 creator A5078153093 @default.
• W2079138963 creator A5078159808 @default.
• W2079138963 creator A5080697191 @default.
• W2079138963 creator A5081241976 @default.
• W2079138963 creator A5082983493 @default.
• W2079138963 creator A5084354003 @default.
• W2079138963 creator A5088998119 @default.
• W2079138963 creator A5089393123 @default.
• W2079138963 date "2012-09-27" @default.
• W2079138963 modified "2023-10-18" @default.
• W2079138963 title "Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial" @default.
• W2079138963 cites W1556628912 @default.
• W2079138963 cites W1978377409 @default.
• W2079138963 cites W1988092780 @default.
• W2079138963 cites W2018729528 @default.
• W2079138963 cites W2026448323 @default.
• W2079138963 cites W2028399237 @default.
• W2079138963 cites W2063697325 @default.
• W2079138963 cites W2075290032 @default.
• W2079138963 cites W2078752778 @default.
• W2079138963 cites W2086653135 @default.
• W2079138963 cites W2101576302 @default.
• W2079138963 cites W2110466835 @default.
• W2079138963 cites W2111159843 @default.
• W2079138963 cites W2117172636 @default.
• W2079138963 cites W2120780398 @default.
• W2079138963 cites W2134902298 @default.
• W2079138963 cites W2135514413 @default.
• W2079138963 cites W2143860449 @default.
• W2079138963 cites W2146000276 @default.
• W2079138963 cites W2171599349 @default.
• W2079138963 cites W4241442958 @default.
• W2079138963 doi "https://doi.org/10.1182/blood-2012-05-427815" @default.
• W2079138963 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22889759" @default.
• W2079138963 hasPublicationYear "2012" @default.
• W2079138963 type Work @default.
• W2079138963 sameAs 2079138963 @default.
• W2079138963 citedByCount "131" @default.
• W2079138963 countsByYear W20791389632012 @default.
• W2079138963 countsByYear W20791389632013 @default.
• W2079138963 countsByYear W20791389632014 @default.
• W2079138963 countsByYear W20791389632015 @default.
• W2079138963 countsByYear W20791389632016 @default.
• W2079138963 countsByYear W20791389632017 @default.
• W2079138963 countsByYear W20791389632018 @default.
• W2079138963 countsByYear W20791389632019 @default.
• W2079138963 countsByYear W20791389632020 @default.
• W2079138963 countsByYear W20791389632021 @default.
• W2079138963 countsByYear W20791389632022 @default.
• W2079138963 countsByYear W20791389632023 @default.
• W2079138963 crossrefType "journal-article" @default.
• W2079138963 hasAuthorship W2079138963A5003094323 @default.
• W2079138963 hasAuthorship W2079138963A5004897410 @default.
• W2079138963 hasAuthorship W2079138963A5006676110 @default.
• W2079138963 hasAuthorship W2079138963A5013472737 @default.
• W2079138963 hasAuthorship W2079138963A5016479494 @default.
• W2079138963 hasAuthorship W2079138963A5020989412 @default.
• W2079138963 hasAuthorship W2079138963A5029159537 @default.
• W2079138963 hasAuthorship W2079138963A5031837957 @default.
• W2079138963 hasAuthorship W2079138963A5034182883 @default.
• W2079138963 hasAuthorship W2079138963A5035866456 @default.
• W2079138963 hasAuthorship W2079138963A5040325515 @default.
• W2079138963 hasAuthorship W2079138963A5047866471 @default.
• W2079138963 hasAuthorship W2079138963A5054952877 @default.
• W2079138963 hasAuthorship W2079138963A5059482051 @default.
• W2079138963 hasAuthorship W2079138963A5073739479 @default.
• W2079138963 hasAuthorship W2079138963A5075422618 @default.
• W2079138963 hasAuthorship W2079138963A5078153093 @default.
• W2079138963 hasAuthorship W2079138963A5078159808 @default.
• W2079138963 hasAuthorship W2079138963A5080697191 @default.
• W2079138963 hasAuthorship W2079138963A5081241976 @default.
• W2079138963 hasAuthorship W2079138963A5082983493 @default.
• W2079138963 hasAuthorship W2079138963A5084354003 @default.
• W2079138963 hasAuthorship W2079138963A5088998119 @default.
• W2079138963 hasAuthorship W2079138963A5089393123 @default.
• W2079138963 hasBestOaLocation W20791389631 @default.
• W2079138963 hasConcept C126322002 @default.
• W2079138963 hasConcept C134018914 @default.
• W2079138963 hasConcept C141071460 @default.
• W2079138963 hasConcept C143998085 @default.

• next